Loading...
HomeMy WebLinkAbout05.07.26 Board Correspondence - FW_ BioNTech to Halt COVID-19 Vaccine Manufacturing, Cut 1,860 Jobs—After $605 Million Quarterly Loss.ATTENTION: This message originated from outside Butte County. Please exercise judgment before opening attachments, clicking on links, or replying.. From:Clerk of the Board To:Mutony, Heather Cc:Lee, Lewis Subject:Board Correspondence - FW: BioNTech to Halt COVID-19 Vaccine Manufacturing, Cut 1,860 Jobs—After $605 Million Quarterly Loss Date:Friday, May 8, 2026 2:16:57 PM Attachments:https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ffcd12649-1db7-4874-ae5a-f69e1eca8979_903x903.png https%3A%2F%2Fsubstack.com%2Ficon%2FLucideHeart%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2 https%3A%2F%2Fsubstack.com%2Ficon%2FLucideComments%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2 https%3A%2F%2Fsubstack.com%2Ficon%2FLucideShare2%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2 https%3A%2F%2Fsubstack.com%2Ficon%2Fnotes__NoteRestackIcon%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2%26strokeLinecap%3Dround%26strokeLinejoin%3Dround https%3A%2F%2Fsubstack.com%2Ficon%2FLucideArrowUpRight%3Fv%3D4%26height%3D36%26fill%3Dnone%26stroke%3D%2523808080%26strokeWidth%3D2 https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F3bfcf039-55b0-49bb-8851-d63529448d58_1456x1048.png image001.png Please see Board Correspondence - Lewis LeeAdministrative Technician - ConfidentialButte County Administration25 County Center Drive, Suite 200 • Oroville, CA 95965T: 530.552.3326www.buttecounty.ca.gov | lelee@buttecounty.ca.gov From: lance dreiss <lancedreiss@att.net> Sent: Thursday, May 7, 2026 12:06 PM To: Shared Mailbox Clerk of the Board <pcbs@countyofplumas.com>; Assemblymember.Gallagher@assembly.ca.gov; Senator.Dahle@senate.ca.gov; davidhollister@countyofplumas.com; sheriff@countyofplumas.com; District Attorney <District_Attorney@buttecounty.ca.gov>; Nicolereinert@countyofplumas.com; Kitts, Melissa <mkitts@buttecounty.ca.gov>; Soderstrom, Monica <msoderstrom@buttecounty.ca.gov>; Durfee, Peter <PDurfee@buttecounty.ca.gov>; Ronald Owens <ronald@muzzledtruth.com>; Kimmelshue, Tod <TKimmelshue@buttecounty.ca.gov>; Pickett, Andy <APickett@buttecounty.ca.gov>; Connelly, Bill <BConnelly@buttecounty.ca.gov>; Teeter, Doug <DTeeter@buttecounty.ca.gov>; Beaudoin, Jarett <JBeaudoin@buttecounty.ca.gov>; Julie Threet <julie4butte5@gmail.com>; Waugh, Melanie <mwaugh@buttecounty.ca.gov>; Ritter, Tami <TRitter@buttecounty.ca.gov>; Teri DuBose <Teri.DuBose@mail.house.gov>; Clerk of the Board <clerkoftheboard@buttecounty.ca.gov>; Stephens, Brad J. <BStephens@buttecounty.ca.gov> Subject: Fwd: BioNTech to Halt COVID-19 Vaccine Manufacturing, Cut 1,860 Jobs—After $605 Million Quarterly Loss Public Record “Follows major German court rulings forcing disclosure of internal COVID vaccine safety and manufacturing records. JON FLEETWOOD MAY 7 READ IN APP BioNTech has announced that it plans to shut down major portions of its COVID-19 vaccine manufacturing network, close multiple facilities, eliminate approximately 1,860 jobs, and consolidate operations as revenues from its COVID-19 vaccine business continue to decline. The move comes after major German court rulings forced BioNTech to hand over internal COVID-19 vaccine safety, toxicity, manufacturing, biodistribution, residual DNA, and spike protein data in vaccine injury litigation, while a higher appellate court overturned a lower ruling favoring the company and ordered a full re- examination of evidence tied to alleged life-altering post-vaccination injuries. According to BioNTech’s official first quarter 2026 financial results press release posted on Tuesday: “BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts.” 1,860 positions in total. The exit from the sites in Idar-Oberstein, Marburg, and Tübingen is planned by the end of 2027, while operations in Singapore are expected to conclude in Q1 2027.” Begin forwarded message: From: Jon Fleetwood <jonfleetwood@substack.com> Date: May 7, 2026 at 10:53:55 AM PDT To: lancedreiss@att.net Subject: BioNTech to Halt COVID-19 Vaccine Manufacturing, Cut 1,860 Jobs—After $605 Million Quarterly Loss Reply-To: Jon Fleetwood <reply+3968dp&kcryl&&60bba6884943afd4c8dfd569eff7bc2de4e9da290fbfc12516820affa7807a80@mg1.substack.com>  Follows major German court rulings forcing disclosure of internal COVID vaccine safety and manufacturing records.͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­͏   ­Forwarded this email? Subscribe here for moreBioNTech to Halt COVID-19 Vaccine Manufacturing, Cut 1,860 Jobs—After $605 Million Quarterly Loss Follows major German court rulings forcing disclosure of internal COVID vaccine safety and manufacturing records. JON FLEETWOOD MAY 7 READ IN APP BioNTech has announced that it plans to shut down major portions of its COVID-19 vaccine manufacturing network, close multiple facilities, eliminate approximately 1,860 jobs, and consolidate operations as revenues from its COVID-19 vaccine business continue to decline. The move comes after major German court rulings forced BioNTech to hand over internal COVID-19 vaccine safety, toxicity, manufacturing, biodistribution, residual DNA, and spike protein data in vaccine injury litigation, while a higher appellate court overturned a lower ruling favoring the company and ordered a full re-examination of evidence tied to alleged life-altering post-vaccination injuries. According to BioNTech’s official first quarter 2026 financial results press release posted on Tuesday: “BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts.” “BioNTech plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac’s sites, affecting up to approximately 1,860 positions in total. The exit from the sites in Idar-Oberstein, Marburg, and Tübingen is planned by the end of 2027, while operations in Singapore are expected to conclude in Q1 2027.” Donate Upgrade to paid Share Follow us on Instagram @realjonfleetwood & Twitter/X @JonMFleetwood. If you value this reporting, consider upgrading to a paid subscription. For advertising & sponsorship opportunities, contact us by clicking below. Message Jon Fleetwood BioNTech also disclosed that it is exploring the sale of the affected facilities: “For each of these manufacturing sites, BioNTech is exploring divestment options, including a partial or total sale.” The company said the restructuring is expected to produce massive long-term cost reductions: “BioNTech expects cost savings to ramp up over time, potentially reaching approximately €500 million in recurring annual savings upon full implementation of the measures in 2029.” The announcement comes as BioNTech reported collapsing COVID-19 vaccine revenues and deepening financial losses. According to the company: “Revenues for the first quarter of 2026 were €118.1 million, compared to €182.8 million for the comparative prior year period. The decrease was primarily driven by lower revenues of BioNTech’s COVID-19 vaccines.” BioNTech also reported: “Net loss was €531.9 million (~$605 Million) for the first quarter of 2026, compared to a net loss of €415.8 million for the comparative prior year period.” The company acknowledged that additional COVID-19 vaccine revenue declines are expected moving forward. “In 2026, BioNTech anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets.” BioNTech further stated: “In Europe, the Company expects lower revenues as it defends its market share and begins managing the transition away from multi-year contracts.” A separate pharmaphorum report published Wednesday stated that BioNTech is effectively winding down COVID-19 vaccine manufacturing operations and shifting production responsibilities to Pfizer. “BioNTech has said it will halt COVID-19 vaccine manufacturing, targeting annual savings of around €500 million, and hand responsibility for producing the shots to its partner Pfizer.” “The announcement came in the German biotech’s first-quarter update, in which it revealed plans to close manufacturing facilities in Germany and Singapore with the loss of around 1,860 jobs – around 22% of its total workforce of 8,400.” At the same time BioNTech is shutting down large portions of its COVID-19 manufacturing infrastructure, the company is aggressively redirecting resources into oncology and mRNA cancer therapeutics. According to BioNTech’s press release: “Operational efficiency to be enhanced through manufacturing footprint consolidation, supporting strategic capital allocation to further advance its growing oncology pipeline toward commercialization.” … “BioNTech will continue to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology.” And CEO Ugur Sahin said: “We will continue to focus on accelerating our key strategic programs as we remain steadfast in our vision to translate our science into survival for patients living with cancer.” Despite the manufacturing shutdowns, BioNTech confirmed it is still preparing updated COVID-19 injections for the upcoming vaccination cycle. “BioNTech is now focused on preparing for variant strain vaccine adaptation to be ready for commercial launch ahead of the upcoming 2026/2027 vaccination season, pending approvals.” Donate Upgrade to paid Share Follow us on Instagram @realjonfleetwood & Twitter/X @JonMFleetwood. If you value this reporting, consider upgrading to a paid subscription. For advertising & sponsorship opportunities, contact us by clicking below. Message Jon Fleetwood German Appellate Court Delivers Devastating Blow to BioNTech in Major Vaccine Injury Case JON FLEETWOOD ·APR 21 Read full story German Court Orders BioNTech to Hand Over 32 Internal Safety, Toxicity, and ManufacturingRecords on ‘Comirnaty’ COVID-19 mRNA Vaccine JON FLEETWOOD ·APR 15 Read full story Moderna to Inject 350 People with Experimental mRNA-1982 Lyme Disease Shot as HumanTrials Expand JON FLEETWOOD ·MAY 4 Read full story Hantavirus PCR Test Sequences Repeatedly Match Human DNA: New BLAST Analysis RaisesFalse Positive Concerns JON FLEETWOOD ·MAY 6 Read full story Leaked CDC Study Claimed COVID Shot Benefit—But Authors Didn’t Even Know Where theImmunity Came From (See Study) JON FLEETWOOD ·APR 30 Read full story WHO Runs Pandemic Simulation 'Exercise Polaris II' JON FLEETWOOD ·MAY 3 Read full story You're currently a free subscriber to JonFleetwood.com. For the full experience, upgrade your subscription. Upgrade to paid LIKE COMMENT RESTACK © 2026 Jon Fleetwood548 Market Street PMB 72296, San Francisco, CA 94104 Unsubscribe